UBE2F-SAG Axis Drives RHEB Neddylation and mTORC1 Activation in Liver Tumorigenesis

Study Background and Research Question

Post-translational modifications are pivotal in regulating protein function, localization, and stability. Among these, neddylation—the covalent attachment of the ubiquitin-like protein NEDD8 to substrate lysines—has emerged as a crucial modulator of various cellular pathways. The mechanistic target of rapamycin complex 1 (mTORC1) is a central regulator of cell growth and metabolism, frequently upregulated in hepatocellular carcinoma (HCC). RHEB, a small GTPase, is a well-established activator of mTORC1, but whether RHEB undergoes neddylation and how this modification influences mTORC1 signaling in liver pathology remained unexplored. The recent study by Zhang et al. (2025) addresses this gap by investigating the role of the UBE2F-SAG neddylation axis in regulating RHEB activity and its impact on liver tumorigenesis.

Key Innovation from the Reference Study

The pivotal innovation of this work lies in the identification of RHEB as a direct substrate for neddylation by the UBE2F-SAG complex. While neddylation's role in cullin-RING ligase regulation had been established, its direct effect on non-cullin substrates implicated in cancer signaling was less clear. Zhang et al. demonstrate that UBE2F, in partnership with the E3 ligase SAG, neddylates RHEB at lysine 169. This modification augments RHEB's lysosomal localization and enhances its GTP-loading—two factors essential for robust mTORC1 activation. The study not only extends the landscape of neddylation substrates but also connects this post-translational modification mechanistically to cancer-driving pathways in the liver.

Methods and Experimental Design Insights

The study employed a multifaceted approach to dissect the neddylation pathway's impact on RHEB and mTORC1:

• Cell culture models with genetic manipulation (siRNA/shRNA-mediated knockdown and CRISPR knockout of UBE2F and SAG) to assess mTORC1 activity, cell cycle progression, and autophagy.
• Biochemical assays, including immunoprecipitation and neddylation-specific immunoblotting, to detect RHEB modification status.
• Site-directed mutagenesis to pinpoint lysine 169 as the critical neddylation site on RHEB.
• Functional analyses of GTP-binding and lysosomal localization using fluorescence microscopy and GTPase assays.
• In vivo mouse models with liver-specific Ube2f knockout, particularly in the context of PTEN loss, to evaluate effects on steatosis and tumor formation.
• Clinical correlation analysis using HCC patient cohorts to relate UBE2F expression and mTORC1 activity to patient outcomes.

By integrating molecular, cellular, in vivo, and clinical data, the study robustly links UBE2F-SAG-mediated neddylation to functional consequences in liver cancer biology.

Core Findings and Why They Matter

Major discoveries from the study include:

• Direct RHEB Neddylation: RHEB is neddylated at K169 by the UBE2F-SAG axis, a modification not previously described for this GTPase (reference).
• Enhanced mTORC1 Signaling: Neddylated RHEB shows increased lysosomal localization and GTP-binding, which synergistically enhance mTORC1 activity, driving cell proliferation and suppressing autophagy.
• Liver Tumorigenesis: Liver-specific deletion of Ube2f in mice attenuates steatosis and tumorigenesis induced by PTEN loss, indicating that UBE2F is an essential driver of mTORC1-dependent liver cancer progression.
• Clinical Relevance: High UBE2F expression and elevated mTORC1 signaling correlate with poorer survival in HCC patients, underscoring the translational significance of this axis.

These findings position UBE2F-SAG-mediated RHEB neddylation as a critical regulatory node in liver cancer, offering new avenues for therapeutic intervention targeting post-translational modification machinery, rather than mTORC1 directly.

Comparison with Existing Internal Articles

Several internal resources discuss the importance of protein purification and detection in studying post-translational modifications such as neddylation. For instance, the article "X-press Tag Peptide: Precision N-terminal Leader for Protein Purification Workflows" emphasizes the utility of N-terminal leader peptides like the X-press Tag Peptide for isolating and studying proteins involved in complex signaling pathways, including those subject to neddylation and mTORC1 regulation. Similarly, "Optimizing Affinity Purification in Recombinant Systems" highlights the benefits of affinity purification using ProBond resin and epitope tags for downstream functional and mechanistic analyses. While these resources focus on technical workflows, the reference study by Zhang et al. expands the biological context by showing how modifications like neddylation can alter protein function and disease progression, underscoring the importance of precise protein isolation for mechanistic investigations.

Limitations and Transferability

Despite its comprehensive design, the study has limitations:

• The direct neddylation of RHEB was demonstrated primarily in liver cancer models. Whether similar mechanisms operate in other cancer types or tissues remains to be elucidated.
• Although strong correlations were observed in patient cohorts, causality in human liver cancer patients requires further validation.
• Potential compensatory mechanisms upon UBE2F inhibition, and the broader substrate spectrum of the UBE2F-SAG axis, are not fully explored.

Nevertheless, the findings are highly transferable to studies investigating post-translational modifications, protein-protein interactions, and signaling pathway regulation in cancer and metabolic disease.

Protocol Parameters

• Genetic Manipulation: Use validated siRNA, shRNA, or CRISPR/Cas9 constructs for UBE2F or SAG knockdown or knockout. Validate efficiency by immunoblotting for target protein loss.
• Neddylation Detection: Employ anti-NEDD8 antibodies for immunoprecipitation and detection of modified proteins. Include appropriate mutant controls (e.g., RHEB K169R).
• Affinity Purification: For recombinant RHEB or pathway component isolation, use N-terminal leader peptides such as the X-press Tag Peptide, followed by affinity purification using ProBond resin and anti-Xpress antibody detection.
• In vivo Models: Generate liver-specific knockout mice using tissue-specific Cre lines and confirm gene ablation by PCR and immunoblotting.
• Clinical Correlation: Analyze patient datasets for UBE2F and mTORC1 pathway signatures. Use survival analysis to link molecular markers to clinical outcomes.

Research Support Resources

To facilitate studies of post-translational modification and protein-protein interactions, researchers can incorporate X-press Tag Peptide (SKU A6010) as an N-terminal leader peptide for recombinant protein expression and purification. Its structure enables high-yield affinity purification using ProBond resin and precise detection with anti-Xpress antibodies, supporting workflows analogous to those described in the reference study. For best results, follow product-specific recommendations regarding peptide solubility in DMSO and storage at -20°C. Leveraging such reagents ensures experimental reproducibility in dissecting signaling pathways regulated by post-translational modifications.